Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Tag: neuromusculoskeletal care

ChiroMedBlogneuromusculoskeletal care
Hormone Health, Metabolism, and Prostate Wellness

Hormone Health, Metabolism, and Prostate Wellness

Hormone Health, Metabolism, and Prostate Wellness

Abstract

In this educational post, I take you through a practical, clinician-tested roadmap to understanding and treating hormone-related metabolic dysfunctions across the lifespan—particularly the interplay among sex hormone–binding globulin (SHBG), insulin resistance, polycystic ovary syndrome (PCOS), DHEA dynamics, and prostate-specific antigen (PSA) decision-making for men’s health. Drawing on current research and my clinical observations at Chiromed and in integrative practice, I explain why SHBG is not your enemy, how gut-driven insulin resistance amplifies androgen effects, how to identify PCOS phenotypes that do not look “typical,” and how to merge modern therapeutics (GLP-1s, metformin, spironolactone) with lifestyle, nutrition, and integrative chiropractic care to restore function. I also walk through PSA interpretation using percent free PSA and velocity, and when to order a 3T multiparametric prostate MRI. You will find physiologic context, step-by-step reasoning, and practical protocols you can apply immediately.

Key topics that follow

  • SHBG physiology, clinical meaning, and why chasing a lower SHBG is usually counterproductive
  • Insulin resistance, the gut–ovary axis, and PCOS phenotypes and treatment logic
  • Practical dosing pearls for metformin, GLP-1 receptor agonists, and spironolactone
  • DHEA physiology, neurological roles, and targeted use in men and women
  • PSA, percent free PSA, velocity, and the role of 3T multiparametric MRI
  • Where integrative chiropractic, movement therapy, and neuromusculoskeletal care fit into endocrine-metabolic care plans

Understanding SHBG, Free Testosterone, and Metabolic Health

I often meet patients who are symptomatic for low testosterone despite “normal” total testosterone. The missing piece is frequently sex hormone–binding globulin (SHBG)—a carrier protein synthesized in the liver that binds androgens (with a higher affinity for testosterone than for estradiol) and regulates the amount of hormone that is free and bioavailable to occupy intracellular receptors.

Core physiology, clearly explained

  • SHBG binds circulating androgens. Bound hormone is transport-ready but not freely available to cross the cell membrane and activate intracellular androgen receptors.
  • The fraction that remains free (or loosely albumin-bound) is bioavailable and exerts physiologic effects in target tissues (muscle, brain, bone, skin, reproductive organs).
  • Hepatic SHBG synthesis is modulated by insulin, estrogen, and thyroid status. Hyperinsulinemia suppresses SHBG; estrogen and thyroid hormone tend to raise it.
  • Clinically, a low SHBG often signals insulin resistance, while a higher SHBG is frequently associated with favorable metabolic profiles.

Why this matters clinically

  • Patients with low SHBG often present with features of metabolic syndrome—even when A1c still looks “fine.” Multiple cohorts show that low SHBG is a predictive marker for insulin resistance, dysglycemia, and cardiometabolic risk in both women and men (Ding et al., 2009; Selva et al., 2007).
  • Chasing a lower SHBG to “free up” testosterone usually misses the root cause and may worsen risk. Raising insulin (e.g., by overeating refined carbohydrates) can drop SHBG, but at a clear metabolic cost.

Evidence snapshot

  • Prospective data indicate that low SHBG predicts incident type 2 diabetes in women and men independent of BMI and baseline glucose (Ding et al., 2009).
  • Mechanistically, hepatic insulin signaling downregulates SHBG gene expression (Selva et al., 2007), providing a direct pathway from insulin resistance to low SHBG.

Treatment logic you can trust

  • Goal: Improve insulin sensitivity and the liver’s metabolic set point rather than artificially forcing SHBG down.
  • When symptomatic hypogonadism coexists with low SHBG, you may need to “saturate” androgen receptors by optimizing total testosterone so that the available free fraction reaches clinical effectiveness. The parallel, long-term fix is to address metabolic drivers that normalize SHBG.

Integrative chiropractic fit

  • In our practice, optimized movement patterns, resistance training, and autonomic balance through chiropractic care and neuromusculoskeletal rehabilitation improve insulin sensitivity, lower systemic inflammation, and support hepatic health—mechanisms that indirectly help normalize SHBG. I find that restoring spinal mechanics and reducing pain enables patients to engage in consistent physical activity, a cornerstone for improving insulin signaling (see my practice observations at Chiromed).

PCOS, Insulin Resistance, and the Gut–Ovary Axis

PCOS is one of the most common endocrine disorders in women of reproductive age. Yet, it is easy to miss because many patients lack the classic triad of obesity, acne, and hirsutism. I routinely see athletic women with irregular cycles, dysmenorrhea, or infertility—sometimes the only obvious clue—who nonetheless have the hormonal signature of PCOS.

Current diagnostic framework

  • Rotterdam criteria: Diagnose PCOS when at least 2 of 3 are present:
    • Oligo- or anovulation (e.g., irregular or skipped cycles)
    • Clinical/biochemical hyperandrogenism (e.g., hirsutism, acne, elevated free testosterone)
    • Polycystic ovarian morphology (PCOM) on ultrasound
  • Note: Not all patients have ovarian cysts, and total testosterone may be normal while free testosterone is elevated due to low SHBG.

Useful lab patterns

  • Elevated LH: FSH ratio (often >2:1) in some premenopausal patients.
  • Low or low-normal SHBG, elevated free testosterone; often high DHEA-S in adrenal-dominant phenotypes.
  • Early insulin abnormalities and low SHBG can precede changes in A1c.

Why insulin resistance drives PCOS

  • Hyperinsulinemia stimulates theca cells in the ovary to increase androgen production while simultaneously suppressing hepatic SHBG synthesis, thereby increasing free androgens (Escobar-Morreale, 2018).
  • Gut dysbiosis and endotoxemia (LPS exposure) promote low-grade inflammation and worsen insulin signaling, propagating ovarian dysfunction (Zhang et al., 2019).

Atypical PCOS phenotypes I see

  • Lean, athletic women with:
    • Severe dysmenorrhea or irregular cycles
    • Elevated LH: FSH
    • High free T with normal total T
    • High DHEA-S
    • Minimal or no hirsutism/acne

This pattern demands a gut–metabolic workup even when body composition appears healthy. I frequently include stool microbiome testing when symptoms suggest dysbiosis.

Evidence-Based Treatment Algorithms for PCOS

My approach integrates metabolic therapy, targeted pharmacology, nutrition, and neuromusculoskeletal care.

  1. Normalize insulin signaling
  • Metformin: Start low (e.g., 500 mg nightly) and titrate slowly to 1,500–2,000+ mg/day as tolerated to reduce hepatic gluconeogenesis and improve insulin sensitivity. GI side effects often attenuate with gradual titration and extended-release forms (Rena et al., 2017).
  • GLP-1 receptor agonists (e.g., semaglutide, exenatide): Improve glucose-dependent insulin secretion, delay gastric emptying, reduce appetite, and facilitate weight loss; randomized trials show improved metabolic and reproductive outcomes in PCOS (Kahal et al., 2021; Elkind-Hirsch et al., 2008).
  • Mechanistic payoff: Lower insulin raises SHBG and reduces androgenic “noise,” restoring ovulatory signaling.
  1. Manage androgenic symptoms while root-cause care takes hold
  • Spironolactone: An aldosterone antagonist with androgen receptor–blocking activity; effective for hirsutism, acne. Typical doses 50–100 mg/day; allow 6–12 months for maximal effect (Brown et al., 2009).
  • Combined oral contraceptives (COCs) with antiandrogenic progestins (e.g., drospirenone-containing formulations) can raise SHBG and reduce free T; useful for cycle control and symptom relief when pregnancy is not desired (Teede et al., 2018).
  • Caution: Symptom control does not correct the insulin–ovary axis; keep metabolic therapy central.
  1. Nutrition, gut health, and inflammation
  • Anti-inflammatory, Mediterranean-style diet with adequate protein, fiber, and omega-3 fatty acids improves insulin sensitivity and reduces ovarian androgen production (Barrea et al., 2019).
  • Intermittent fasting (time-restricted eating) may improve insulin sensitivity and weight in appropriately selected patients; ensure adequate caloric intake and avoid in those with disordered eating tendencies (Patterson & Sears, 2017).
  • Microbiome support: Address dysbiosis, SIBO, and intestinal permeability where indicated; diet, prebiotic fiber, and evidence-based probiotics can improve metabolic parameters.
  1. Movement and integrative chiropractic
  • Consistent resistance training and aerobic exercise improve GLUT4 translocation, mitochondrial function, and insulin sensitivity. In my clinic, we pair individualized spinal and joint care with corrective exercise to reduce pain-related movement avoidance and enhance adherence.
  • Autonomic balance matters: Many PCOS patients show sympathetic dominance; hands-on care and breathing-based neuromuscular retraining can reduce allostatic load and support ovulatory recovery.
  1. Fertility trajectory
  • Expect cycles and ovulation to normalize over months to years as insulin sensitivity improves. I have seen patients regain regular ovulation and conceive after systematic, sustained metabolic and gut care—even in those previously considered “lean and healthy.”

Clinical pearls and cautions

  • Start androgen therapy cautiously in PCOS or insulin-resistant women with low SHBG. Given the higher free fraction, standard doses can overshoot, increasing the risk of side effects. Start low and titrate slowly if testosterone therapy is clinically indicated for other reasons.
  • Obtain LH and androgen panels in premenopausal patients with menstrual complaints or infertility—even if phenotype is nonclassic.
  • Consider GI testing (e.g., stool analysis) when symptoms or history suggest dysbiosis, IBS, or food-triggered inflammation.

SHBG: What to Avoid and What to Embrace

Common misconception

  • “Lower SHBG to increase free T.” This treats the lab number, not the disease process.

What to avoid

  • Strategies that raise insulin (e.g., high refined carbohydrate load) just to lower SHBG.
  • Unnecessary suppression of SHBG may worsen cardiometabolic risk.

What to embrace

  • Improve insulin sensitivity through nutrition, exercise, sleep optimization, stress modulation, and gut care.
  • Use medications like metformin and GLP-1 receptor agonists to shift the metabolic field when lifestyle alone is insufficient.

In my practice, when we prioritize insulin sensitivity and inflammation control, SHBG trends upward into healthier ranges, free testosterone normalizes relative to total testosterone, and symptoms improve without chasing lab artifacts.

PSA, Percent Free PSA, and Prostate MRI: Smarter Men’s Health

PSA screening has evolved. A single total PSA value is an imperfect signal. Two tools improve decision-making:

  • Percent free PSA (%fPSA): The fraction of PSA not bound to serum proteins. Lower %fPSA indicates a higher likelihood of malignancy at a given total PSA.
  • PSA velocity: The year-over-year change in PSA. Faster rises suggest higher risk.

How I interpret PSA in practice

  • If total PSA is elevated (e.g., >4.0 ng/mL), I obtain percent free PSA. General rules supported by meta-analyses:
    • %fPSA <10% = higher probability of prostate cancer
    • %fPSA 10–20% = intermediate zone; consider prostatitis treatment if symptomatic and retest in ~3 months
    • %fPSA >20% = lower probability; continue surveillance
  • Consider PSA velocity: An increase >0.35–2.0 ng/mL/year—context-dependent—merits further evaluation even if the absolute PSA is “within range” (Vickers et al., 2011).
  • Many benign factors elevate total PSA—intercourse, cycling, digital stimulation, BPH, prostatitis—but they do not significantly affect %fPSA, which is why I lean on percent free PSA for triage.

Imaging that changes outcomes

  • If risk remains concerning (low %fPSA, rapid velocity, suspicious DRE, or persistent PSA elevation), I order a 3 Tesla multiparametric prostate MRI (mpMRI). This modality improves lesion detection and helps target biopsies, reducing unnecessary procedures (Ahmed et al., 2017).
  • Most patients prefer an MRI over immediate biopsy, and mpMRI adds diagnostic clarity, including detection of chronic or acute prostatitis—a common cause of PSA bumps that I diagnose frequently.

Practical pearls

  • Finasteride lowers total PSA by roughly ~50% but does not meaningfully change %fPSA—interpretation should be adjusted accordingly.
  • Counsel patients to avoid prostate stimulation (e.g., ejaculation, vigorous cycling) for 48–72 hours before PSA sampling to reduce noise in total PSA.
  • If PSA and %fPSA suggest low risk, recheck in 3 months rather than rushing to biopsy.

Testosterone therapy timing

  • When PSA and urologic evaluation are reassuring, testosterone therapy can proceed with routine monitoring. I coordinate closely with urology, recognizing that practice styles vary.

DHEA Physiology, Brain Receptors, and When to Treat

Dehydroepiandrosterone (DHEA) and its sulfated form, DHEA-S, are produced primarily by the adrenal cortex and function as both endocrine prohormones and neurosteroids, with receptors and actions in the brain. Levels peak in the 20s and decline steadily with age. In both sexes, suboptimal DHEA can present as low vitality, depressed mood, impaired stress tolerance, and reduced sexual function—even when testosterone looks “good.”

Why DHEA matters

  • Neurosteroid action: DHEA modulates GABAergic and glutamatergic tone, supporting mood, cognition, and arousal (Maninger et al., 2009).
  • Peripheral conversion: DHEA can be converted to androgens and estrogens via tissue-specific enzymes; in women, a portion is converted to DHT in peripheral tissues, contributing to libido and sexual response.
  • Immunometabolic effects: DHEA has anti-inflammatory properties and may influence endothelial function and bone metabolism.

Clinical patterns I see

  • Women with adequate total and free testosterone who remain symptomatic for low libido or anorgasmia sometimes have low DHEA-S in the double digits. Carefully titrated DHEA supplementation often improves sexual function and overall well-being.
  • In men and women with persistent fatigue and low mood despite thyroid/hormone optimization, DHEA can be the missing link.

Dosing logic

  • I typically optimize thyroid and sex hormones first; DHEA often rises when metabolic stress decreases.
  • If DHEA-S remains suboptimal:
    • Women: 5–10 mg/day compounded DHEA; reassess at ~6 weeks
    • Men: 20 mg/day compounded DHEA; reassess at ~6 weeks
    • Over-the-counter options vary in potency; when used, I start around 25 mg/day with close follow-up.
  • Monitor for androgenic side effects, especially in PCOS (who often already have high DHEA-S); avoid in hyperandrogenic phenotypes.

Evidence notes

  • Studies link low DHEA-S to reduced well-being, depression, and sexual dysfunction, with improvements seen in targeted supplementation cohorts (Arlt et al., 1999; Wierman et al., 2014). Age-associated decline is robust and correlates with multiple health outcomes.

Why Integrative Chiropractic Care Belongs in Endocrine-Metabolic Programs

The neuromusculoskeletal system interfaces with the endocrine and immune systems through shared inflammatory and autonomic pathways. Here is how integrative chiropractic care fits, based on observations from my clinic and the scientific literature:

Mechanistic bridges

  • Inflammation: Chronic pain amplifies IL-6 and TNF-α signaling, worsening insulin resistance. By reducing nociceptive drive and improving joint mechanics, manual therapies can lower inflammatory load and facilitate activity.
  • Autonomic balance: Spinal and rib mechanics influence sympathetic/parasympathetic tone. Improved thoracic mobility and diaphragmatic function promote vagal activity, which supports glycemic control and gut motility—both key to the gut–ovary axis.
  • Movement competency: Targeted strength and mobility programs enhance GLUT4 activity in skeletal muscle, thereby improving insulin sensitivity and supporting healthy SHBG levels.

In practice at Chiromed

  • We build individualized plans that synchronize:
    • Spinal and extremity joint care to enable pain-free training
    • Progressive resistance training emphasizing posterior chain and hip mechanics
    • Aerobic conditioning at sustainable intensities
    • Breathing retraining and sleep hygiene to normalize cortisol rhythms
  • This approach improves adherence to metabolic prescriptions, enabling the nutrition and pharmacology to “land” in real life.

Search-optimized section title Practical Protocols and Case-Style Reasoning

Putting it all together, here is how I apply the logic in daily care.

When SHBG is low, and symptoms suggest androgen deficiency

  • Evaluate metabolic health: fasting insulin, lipids, liver enzymes, hs-CRP, A1c.
  • Address insulin resistance first-line with nutrition, exercise, sleep, and stress management; consider metformin and/or GLP-1 RAs.
  • If symptoms persist, carefully optimize testosterone with awareness that low SHBG increases free fraction—start low, titrate to symptom relief and physiologic targets.

When PCOS is likely, but the phenotype is atypical

  • Order LH, FSH, total and free T, SHBG, DHEA-S, fasting insulin/glucose, and consider stool testing.
  • Begin metabolic therapy plus symptom-directed therapy (spironolactone or COCs if appropriate and pregnancy not desired).
  • Integrate resistance training and chiropractic-guided movement plans to accelerate insulin sensitivity and ovulatory recovery.

When initiating or adjusting DHEA

  • Confirm suboptimal DHEA-S and symptom alignment (low mood, libido, vitality).
  • Start low, reassess in 6–8 weeks, and monitor for androgenic side effects.
  • Avoid in hyperandrogenic PCOS unless clearly indicated and monitored.

When PSA is elevated or changing fast

  • Obtain percent free PSA and calculate velocity.
  • If %fPSA <10% or velocity is concerning, proceed to 3T mpMRI; if prostatitis is suspected, treat and retest.
  • Collaborate with urology based on mpMRI and clinical findings; delay testosterone changes until evaluation clarifies risk.

Why We Use Each Technique: The Physiology Behind the Protocols

  • Metformin: Reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity via AMPK activation; lowers insulin, allowing SHBG to normalize and free T to calm down.
  • GLP-1 receptor agonists: Enhance glucose-dependent insulin secretion, reduce appetite, and reduce systemic inflammation; improved ovulatory function reported in PCOS.
  • Spironolactone: Direct androgen receptor blockade plus inhibition of 5α-reductase at higher doses; symptom relief while metabolic causes are corrected.
  • DHEA: Restores neurosteroid tone and supports sexual function with selective peripheral conversion; used when clinically and biochemically indicated.
  • Integrative chiropractic and movement: Improves neuromechanics and reduces pain, enabling training volume and intensity that improve insulin sensitivity; enhances autonomic balance affecting gut and endocrine axes.

Final Takeaways for Patients and Providers

  • Think metabolically first: Low SHBG is often a metabolic distress signal, not a target to suppress.
  • PCOS can be lean and subtle: Free T, LH: FSH, and DHEA-S mapping, plus gut assessment, can catch atypical cases.
  • Combine symptom control and root-cause therapy: Use spironolactone or COCs for hirsutism/acne while you restore insulin sensitivity and gut health.
  • Use smarter PSA strategies: Percent free PSA and PSA velocity reduce unnecessary biopsies and guide timely imaging with 3T mpMRI.
  • Integrate care: When manual therapy, structured exercise, and metabolic medicine are aligned, recovery timelines shorten and outcomes improve.

References

Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., … Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822.

Arlt, W., Callies, F., van Vlijmen, J. C. M., Koehler, I., Reincke, M., Bidlingmaier, M., … Allolio, B. (1999). Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341(14), 1013–1020.

Barrea, L., Marzullo, P., Muscogiuri, G., Di Somma, C., De Alteriis, G., Colao, A., & Savastano, S. (2019). Nutritional aspects of PCOS: an update. Advances in Nutrition, 10(2), 270–292.

Brown, J., Farquhar, C., Lee, O., Toomath, R., & Jepson, R. (2009). Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews, (2), CD000194.

Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C.-C., Rifai, N., … Liu, S. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. JAMA, 301(17), 1777–1786.

Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008). Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in obese polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 93(7), 2670–2678.

Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Human Reproduction Update, 24(6), 671–698.

Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., & Kilpatrick, E. S. (2021). The effect of GLP-1 receptor agonists on cardiovascular risk factors in women with PCOS. Endocrine, 71, 199–206.

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of DHEA and DHEA-S. Psychoneuroendocrinology, 34(3), 273–286.

Patterson, R. E., & Sears, D. D. (2017). Metabolic effects of intermittent fasting. Annual Review of Nutrition, 37, 371–393.

Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Nature Reviews Molecular Cell Biology, 19(1), 31–44.

Selva, D. M., Hogeveen, K. N., Innis, S. M., & Hammond, G. L. (2007). Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone–binding globulin gene. Journal of Clinical Investigation, 117(12), 3979–3987.

Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., … International PCOS Network. (2018). Recommendations from the international evidence-based guideline for the assessment and management of PCOS. Human Reproduction, 33(9), 1602–1618.

Vickers, A. J., Savage, C., O’Brien, M. F., Lilja, H. (2011). Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Journal of Clinical Oncology, 29(33), 447–453.

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the science and practice of optimizing hormones by treating the gut–liver–hormone axis and reinforcing micronutrient and mitochondrial foundations. I explain how dysbiosis, intestinal permeability, and microbial enzymes like beta-glucuronidase reshape estrogen metabolism and influence conditions such as PCOS, endometriosis, and autoimmunity, and how lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs) affect insulin sensitivity, mood, and inflammation. I translate current research on vitamin D, K2, iodine, selenium, methylated B vitamins, DIM, and shilajit into clinic-ready protocols, and I show where integrative chiropractic care fits by supporting vagal tone, motility, neuromusculoskeletal dynamics, and autonomic balance. You will find practical frameworks, dosing concepts, lab-monitoring advice, and rationale for each intervention, with citations to leading researchers.

Why Hormones Are Microbiome-Dependent: The Gut–Liver–Hormone Axis

When I first connected hormone symptoms to gut physiology, I saw a pattern: many “hormone” problems began as microbiome and barrier problems. The gut microbiome—a complex community of bacteria, viruses, fungi, and archaea—regulates digestion, immune tolerance, barrier integrity, and the enterohepatic circulation that clears estrogens. From the earliest studies linking metabolic endotoxemia to insulin resistance, it has become clear that LPS-driven inflammation can disrupt cardiometabolic and reproductive health (Cani et al., 2007).

  • When the microbiome is balanced, commensals generate SCFAs (notably butyrate) that nourish colonocytes, tighten junctions, and reduce inflammatory signaling.
  • When dysbiosis develops, beta-glucuronidase-producing taxa expand, and LPS permeates, amplifying NF-κB cytokine cascades that alter hormone receptors, hepatic detoxification, and insulin signaling (Fasano, 2012; Slyepchenko et al., 2017).

Clinically, if you manage estrogen symptoms, insulin resistance, or autoimmune patterns, you are managing the microbiome—whether you realize it or not.

Dysbiosis and Leaky Gut Explained: Distinct Problems that Reinforce Each Other

Two related but distinct issues commonly coexist:

  • Dysbiosis: A shift away from beneficial microbes, with loss of diversity and expansion of pathobionts. Consequences include increased LPS, altered bile acid signaling, and elevated beta-glucuronidase.
  • Leaky gut (increased intestinal permeability): Disruption of tight junction proteins (occludin, claudins, ZO-1) allows antigens and endotoxins to enter circulation, thereby increasing systemic inflammation and immune activation (Fasano, 2012).

Why that matters for hormones:

  • LPS activates TLR4–NF-κB, increasing TNF-α, IL-1β, and IL-6—cytokines that reduce insulin signaling and alter steroid hormone receptor function (Cani et al., 2007).
  • Permeability increases immune load and oxidative stress, thereby consuming methyl donors and glutathione needed for safe phase II detox (methylation, glucuronidation, sulfation) of estrogens.

I screen for these drivers whenever patients report PMS, heavy cycles, PCOS features, endometriosis pain, acne or hair loss, mood changes, fatigue, or autoimmune flares. Correcting the gut often increases the safety and efficacy of hormone therapy.

Estrogen Metabolism 101: Enterohepatic Circulation and the Estrobolome

The liver metabolizes estrogens via phase I hydroxylation (CYP1A1, CYP1B1) and phase II conjugation (COMT methylation, glucuronidation, sulfation). Conjugated metabolites pass into bile and should be excreted. In dysbiosis, microbial beta-glucuronidase deconjugates these estrogens, promoting reabsorption and recirculation—the biochemical basis of “estrogen dominance,” even with careful dosing (Plottel & Blaser, 2011).

  • 2-hydroxylation generally produces less proliferative metabolites.
  • 4- and 16α-hydroxylation yield more proliferative or potentially genotoxic metabolites if methylation and conjugation are suboptimal.

In complex cases or when there is a family history of estrogen-dependent cancers, I consider urinary metabolite testing to map pathways and guide targeted support.

PCOS, Endometriosis, and Autoimmunity: What the Microbiome Adds

Recent studies sharpen the microbiome’s role:

  • PCOS: Dysbiosis with fewer SCFA producers and higher LPS correlates with insulin resistance, hyperandrogenism, and impaired GLP-1 signaling (Lindheim et al., 2017; Qi et al., 2019). Restoring butyrate producers improves metabolic tone.
  • Endometriosis: Altered microbiota, increased permeability, and immune activation correlate with symptom severity. Increased beta-glucuronidase raises estrogen recirculation that can exacerbate lesions and pain (Chen et al., 2017; Jiang et al., 2017).
  • Autoimmunity: Barrier dysfunction and loss of tolerogenic species permit pathobiont translocation and molecular mimicry, priming autoimmune activity (Manfredo Vieira et al., 2018).

Clinical translation: Addressing the gut can reduce hormone dosing requirements, expand the therapeutic window, and stabilize mood, sleep, and metabolism.

The Simple Question with Big Impact: Are You Pooping Daily?

I ask every patient: “Do you have a daily bowel movement?”

  • Estrogen metabolites exit via bile and stool. Constipation increases residence time, giving beta-glucuronidase more opportunity to deconjugate and recirculate estrogens.
  • Correcting bowel habits is a core risk-reduction strategy for estrogen-driven conditions.

Practical steps I use:

  • Increase hydration and electrolytes.
  • Ramp fiber to 25–35 g/day; add PHGG (partially hydrolyzed guar gum) 4–6 g/day for low-bloat prebiotic support.
  • Add magnesium glycinate or citrate at night for stool regularity and sleep.
  • Encourage postprandial walks and vagal toning (slow exhale breathing, humming).

A 3-by-3 Framework for Gut Repair: Remove, Replace, Repair

To keep things doable, I use a 3-by-3 approach:

  1. Remove/Reduce Irritants
  • Clean up the diet: favor whole foods; limit alcohol, ultra-processed items, added sugars; consider a gluten-light or gluten-free trial for sensitive individuals.
  • Medication review: minimize NSAIDs and PPI overuse when clinically safe.
  • Stress load: hard-wire breath work, walks, and sleep hygiene.
  1. Replace and Restore
  • Fiber and prebiotics: 25–35 g/day total fiber; add PHGG for gentle SCFA support.
  • Probiotics: multi-strain Lactobacillus and Bifidobacterium blends (e.g., L. rhamnosus GG, B. lactis) for barrier and immune balance.
  • Digestive support: bitters and meal hygiene for hypochlorhydria/slow motility; phosphatidylcholine and balanced fats for bile flow.
  1. Repair and Rebalance
  • Barrier repair: L-glutamine 5 g/day, zinc carnosine, N-acetyl-D-glucosamine, omega-3s as indicated.
  • Inflammation control: Berberine for dysbiosis-associated endotoxemia; curcumin and quercetin for NF-κB calming.
  • Lifestyle anchors: 150 minutes/week activity; 10-minute post-meal walks; consistent 7–9 hours of sleep.

Why this approach works:

  • Prebiotics increase SCFAs, reinforce tight junctions, and support T-regs via HDAC inhibition.
  • Probiotics competitively inhibit pathobionts, reduce beta-glucuronidase activity, and enhance mucosal IgA.
  • L-glutamine fuels enterocytes and accelerates barrier recovery.
  • Berberine improves the microbial balance and activates AMPK to improve insulin sensitivity.

Nutrient Foundations for Receptor-Level Hormone Action: D, K2, A, Magnesium, Iodine, Selenium, and Methylation

I frequently see patients with robust serum hormones but poor tissue effects. The missing link is often receptor signaling, cofactors, and membranes.

  • Vitamin D3 behaves like a secosteroid hormone that modulates transcription through the VDR. Low vitamin D is associated with all-cause and cardiovascular mortality and can blunt androgen signaling even when total testosterone appears normal (Pilz et al., 2011; Holick, 2017).
  • Magnesium is a cofactor for D activation (25- and 1α-hydroxylases); deficiency dampens VDR signaling (Rosanoff et al., 2016).
  • Vitamin K2 directs calcium into bone and away from soft tissues by activating matrix Gla protein and osteocalcin; it complements D to protect vessels and build bone (Schurgers & Vermeer, 2000; Beulens et al., 2013).
  • Vitamin A supports epithelial integrity, immune balance, and nuclear receptor synergy with vitamin D.

I often use an ADK formula (D3 with K2 and A) alongside magnesium to safely improve receptor-mediated effects, while monitoring 25(OH)D, calcium, and PTH (Rosen et al., 2012).

Thyroid resilience: iodine and selenium synergy

  • Iodine is essential for T4/T3 synthesis, but safe utilization depends on selenium-dependent enzymes (glutathione peroxidases, thioredoxin reductases) to quench the H2O2 generated during iodide organification (Ventura et al., 2017).
  • Inadequate selenium increases oxidative stress at the thyroid, raising the risk of autoimmunity when iodine intake rises (Gartner & Gasnier, 2003).
  • I pair iodine (200–400 mcg) with selenium (100–200 mcg selenomethionine) and often zinc (10–30 mg), titrated to labs and symptoms (Zimmermann & Boelaert, 2015).

Methylation for estrogen safety

  • Methylated B vitamins—methylfolate and methylcobalamin—support COMT-mediated methylation of catechol estrogens, reducing genotoxic stress and stabilizing phase II clearance.

These micronutrients are the bedrock that allows hormones to “dock” and trigger healthy cellular responses.

DIM and Estrogen Metabolites: Steering Toward Safer Pathways

Diindolylmethane (DIM) shifts estrogen metabolism toward 2-hydroxylation and away from 16α- and 4-hydroxylation pathways associated with proliferative and genotoxic risk (Zeligs et al., 2006; Reed et al., 2006). Preclinical studies suggest that DIM may also upregulate BRCA1 signaling and promote apoptosis in cancer cell lines (Fan et al., 2009; Li et al., 2010).

How I apply it:

  • Women with estrogen-dominant symptoms or unfavorable metabolite profiles: 150–300 mg/day, adjusted to labs and tolerance.
  • Men with prostate risk or aromatization-driven symptoms: 300–600 mg/day, personalized.
  • I pair DIM with omega-3s, iodine/selenium, and fiber/probiotics to support the entire estrobolome–liver–stool axis.

Rationale: By changing metabolite balance and supporting conjugation, DIM decreases receptor overstimulation and DNA-adduct risk while improving symptom stability.

Shilajit for Free Testosterone and Mitochondrial Support

Some patients—particularly young males—present with high total testosterone but low free testosterone and low vitality. Shilajit, a purified, fulvic-acid–rich resin, has randomized data showing increases in total (~31%), free (~51%), and DHT (~37%) over ~90 days at 250 mg twice daily (Pandit et al., 2016). Mechanisms likely include improved mitochondrial function, nutrient transport, and hypothalamic–pituitary–gonadal signaling.

How I use it:

  • In those seeking endogenous support without exogenous hormones, I combine shilajit with vitamin D, magnesium, zinc, B12, and iodine/selenium when indicated, then track changes in free T, SHBG, energy, and body composition.

Why this works: Enhancing mitochondrial ATP and cofactor availability raises tissue responsiveness; changes in binding dynamics can increase the bioactive fraction without pushing total testosterone to excessive levels.

Vitamin D as a Systemic Modulator: Barrier, Immunity, and Receptors

I routinely optimize vitamin D because it acts at the intersection of immunity, barrier integrity, and endocrine signaling. Observational data tie suboptimal 25(OH)D to higher risks across diseases (Bouillon et al., 2019). Mechanistically, D supports tight junction proteins, cathelicidin, and endocrine receptor sensitivity. Clinically, many patients feel “stuck” until D is restored to an optimal range; I often target 60–80 ng/mL with appropriate monitoring to avoid hypercalcemia (Holick, 2017; Rosen et al., 2012).

Integrative Chiropractic Care: The Neuroimmune–Endocrine Interface

As a chiropractor and nurse practitioner, I see daily how autonomic balance, fascial mobility, and pain modulation determine whether patients can absorb nutrients, move consistently, and sleep well—foundations for endocrine success.

  • Vagal tone and motility: Gentle spinal and cervical adjustments can influence autonomic balance, improving gut motility, secretory IgA, and anti-inflammatory vagal pathways. Patients with low vagal tone present with constipation, bloating, and poor stress resilience.
  • Fascia and diaphragm: Thoracolumbar fascial restrictions and diaphragmatic stiffness impair breathing mechanics and lymphatic flow, promoting sympathetic overdrive. Mobility restores circulation and reduces pain.
  • Pain reduction without NSAIDs: Lowering nociception decreases cortisol and protects the mucosa from NSAID-induced permeability.
  • Behavioral activation: When pain decreases, patients walk, train, and sleep—activities that increase SCFAs, improve insulin sensitivity, and stabilize mood.

These neurophysiologic effects align with published observations on autonomic modulation and musculoskeletal care (Pickar, 2002; Lehman et al., 2012) and help nutrition and endocrine strategies “stick” in daily life.

For examples of how we operationalize this, see my resources at Chiromed and my professional updates on LinkedIn.

A Phased, Clinic-Ready Protocol for Gut and Hormone Optimization

I layer care to build momentum and safety.

Phase 1: Stabilize and Build Trust (Weeks 0–4)

  • Ensure daily bowel movements; add PHGG, hydration, and magnesium as needed.
  • Start a multi-strain probiotic (Lactobacillus + Bifidobacterium).
  • Begin vitamin D3 with K2 and magnesium; consider ADK formulations.
  • Introduce walks after meals and fixed sleep schedules.
  • Provide chiropractic adjustments and diaphragmatic work to normalize autonomics and reduce pain.
  • Baseline labs: CBC, CMP, 25(OH)D, calcium, PTH, thyroid panel (TSH, free T4/T3), thyroid antibodies as needed, ferritin, B12, folate, magnesium, zinc, selenium, CRP, fasting insulin/glucose, lipid profile, estradiol, total and free testosterone, SHBG.

Phase 2: Targeted Gut Repair and Hormone Pathways (Weeks 4–12)

  • Add L-glutamine 5 g/day for barrier support when indicated.
  • Short berberine course for endotoxemia/dysbiosis; replete with probiotics.
  • Add DIM if clinical or metabolite data show proliferative pathways.
  • Start a methylated B complex to support COMT and phase II detox.
  • Maintain chiropractic care cadence for autonomic and biomechanical resilience.

Phase 3: Personalize, Monitor, and Maintain (Months 3+)

  • Reassess symptoms, bowel habits, and targeted labs; titrate to the lowest effective doses.
  • Reinforce lifestyle anchors: fiber intake, movement, sleep, and stress practices.
  • Schedule periodic tune-ups for the spine, fascia, and breath mechanics to sustain vagal tone and support recovery.

This sequencing respects physiology and behavior: patients feel better first, then commit to more significant changes—resulting in better adherence and durable outcomes.

Special Focus: PCOS and Endometriosis

PCOS

  • Emphasize insulin sensitization through fiber, postprandial walks, resistance training, and, where appropriate, berberine.
  • Reduce LPS: probiotics, polyphenols, and barrier repair to lower endotoxemia.
  • Consider inositols for ovulatory support alongside gut therapy.
  • Monitor androgenic symptoms as gut protocols progress; improvements often track with better bile acid and SCFA signaling.

Endometriosis

  • Reduce beta-glucuronidase pressure via probiotics and fiber to limit estrogen recirculation.
  • Calm neuroimmune inflammation with omega-3s, curcumin, and sleep optimization.
  • Use gentle movement and manual therapy to address pelvic floor tension and diaphragm mobility; sympathetic downshift reduces pain tone.
  • Coordinate with gynecology; gut protocols augment, not replace, indicated care.

Case Reflection: High Total Testosterone, Low Vitality

I saw an 18–19-year-old male with low mood, low energy, weight gain, and “low-T” symptoms. His total testosterone was ~900 ng/dL—clearly not low. What we found: very low vitamin D, low B12, and signs of micronutrient insufficiency. I started a robust B-complex, ADK (D3 + K2 + A), iodine paired with selenium, and magnesium. At follow-up, his mother said, “He’s a totally different person.” Energy, mood, and cognition improved, and multiple medications were discontinued. The physiology: hormones were present, but receptor signaling and cellular machinery were underpowered. Restoring micronutrients enabled the hormones to “work.”

In other young men with high total but low free testosterone, I have added shilajit and structured resistance training. Free fractions improved, and vitality followed—without pushing total testosterone into excess.

Safety, Lab Monitoring, and Personalization

  • Monitor: 25(OH)D, calcium, PTH for vitamin D repletion; thyroid panel and antibodies for iodine–selenium strategies; ferritin, B12, folate, magnesium, zinc, selenium, CRP for micronutrient and inflammatory status; sex hormones including free testosterone and SHBG.
  • Adjust doses to labs and symptoms. If vitamin D stays low despite oral dosing, assess bile flow, fat absorption, and adherence; consider supervised loading.
  • Cautions:
    • Vitamin A: avoid hypervitaminosis; use caution in pregnancy.
    • Iodine: go slowly with autonomous nodules or hyperthyroidism; collaborate with endocrinology.
    • Zinc: long-term high dosing can lower copper; keep the balance.
    • DIM and shilajit: use third-party-tested products; personalize the dose.
    • Berberine: short targeted courses; watch for GI sensitivity and drug interactions.

How Integrative Chiropractic Care Complements Endocrine and Gut Strategies

Mechanistically, chiropractic-informed care bridges biochemistry and behavior:

  • Reduces nociception and sympathetic overdrive, lowering cortisol drag on thyroid conversion and gonadal axes (Lehman et al., 2012).
  • Improves respiratory mechanics and fascial glide, supporting lymphatic flow, nutrient delivery, and waste clearance.
  • Enhances vagal tone, supporting motility, secretory IgA, and peristalsis—foundations for microbiome stability.
  • Facilitates movement prescriptions (resistance training, mobility, aerobic intervals) that reduce aromatase activity, improve insulin sensitivity, and raise androgen receptor density.

In my practice, patients combining endocrine protocols with spinal–fascial optimization report better sleep, steadier energy, more predictable lab trajectories, and lower required doses—an elegant synergy of systems biology and hands-on care. Explore our integrative approach at Chiromed and my professional notes on LinkedIn.

Why Each Technique Matters: Systems Biology Rationale

  • Fiber/PHGG: Feeds SCFA producers, tightens junctions, and supports GLP-1 signaling.
  • Probiotics: Reduce beta-glucuronidase, improve barrier integrity, and temper endotoxemia.
  • L-glutamine: Primary fuel for enterocytes; accelerates epithelial repair.
  • Berberine: Reshapes the gut microbiota, lowers LPS levels, and activates AMPK to improve insulin sensitivity.
  • DIM: Steers estrogen toward 2-hydroxylation, lowering proliferative load.
  • Methylated B vitamins: Enable COMT activity and conjugation; reduce genotoxicity of catechol estrogens.
  • Vitamin D + K2 + A + Mg: Align receptor signaling and calcium kinetics; protect vessels and bone.
  • Iodine + selenium: Support thyroid synthesis while detoxifying H2O2 to prevent autoimmune escalation.
  • Shilajit: Enhances endogenous androgens via mitochondrial and HPG-axis support.
  • Chiropractic care: Normalizes autonomic function, reduces pain, and supports movement habits that sustain microbiome and endocrine gains.

Each intervention nudges a different lever; together, they realign the system.

Clinical Observations from Practice

Across patient cohorts at my clinic, we see reproducible patterns:

  • Resolving constipation reduces PMS and “estrogen rollercoaster” symptoms within weeks.
  • Regular adjustments correlate with improved sleep and stress tolerance, enabling consistent training and meal timing that benefit the microbiome.
  • Vitamin D optimization often coincides with improved mood, less joint pain, and better responses to both gut and hormone protocols.

These observations are consistent with the mechanistic and clinical literature, reinforcing the rationale for why foundational steps deliver outsized results. For more, visit Chiromed and my LinkedIn updates.

References